X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6488) 6488
Publication (720) 720
Book Review (59) 59
Book Chapter (31) 31
Newsletter (17) 17
Book / eBook (12) 12
Conference Proceeding (8) 8
Dissertation (4) 4
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4050) 4050
topoisomerase ii inhibitors (2360) 2360
animals (2232) 2232
index medicus (2087) 2087
antineoplastic agents - pharmacology (1524) 1524
pharmacology & pharmacy (1499) 1499
oncology (1395) 1395
biochemistry & molecular biology (1242) 1242
dna topoisomerases, type ii - metabolism (1229) 1229
enzyme inhibitors - pharmacology (1206) 1206
chemistry, medicinal (1047) 1047
cell line, tumor (982) 982
mice (963) 963
apoptosis (933) 933
cancer (927) 927
topoisomerase i inhibitors (882) 882
dna damage (847) 847
etoposide - pharmacology (814) 814
dna (797) 797
structure-activity relationship (776) 776
female (764) 764
topoisomerase-ii (731) 731
apoptosis - drug effects (694) 694
tumor cells, cultured (692) 692
dose-response relationship, drug (640) 640
camptothecin - pharmacology (597) 597
topoisomerase ii inhibitors - pharmacology (592) 592
male (575) 575
etoposide (574) 574
dna topoisomerases, type i - metabolism (573) 573
antineoplastic agents - chemistry (557) 557
cytotoxicity (555) 555
dna - metabolism (549) 549
chemotherapy (515) 515
cell biology (508) 508
molecular structure (495) 495
camptothecin (486) 486
anti-bacterial agents - pharmacology (477) 477
drug screening assays, antitumor (469) 469
cell survival - drug effects (468) 468
cell line (459) 459
inhibitors (456) 456
cell proliferation - drug effects (444) 444
mutation (433) 433
drug resistance (431) 431
research (429) 429
microbiology (427) 427
antineoplastic agents, phytogenic - pharmacology (426) 426
dna topoisomerase (424) 424
mechanism (415) 415
antineoplastic agents - chemical synthesis (408) 408
derivatives (405) 405
dna topoisomerases, type ii - genetics (405) 405
research article (402) 402
cells (400) 400
expression (398) 398
topoisomerase ii (397) 397
microbial sensitivity tests (395) 395
drugs (386) 386
cell cycle - drug effects (375) 375
inhibition (374) 374
in-vitro (367) 367
analysis (364) 364
proteins (359) 359
camptothecin - analogs & derivatives (355) 355
dna topoisomerase-ii (347) 347
neoplasms - drug therapy (345) 345
enzymes (339) 339
chemistry, organic (338) 338
deoxyribonucleic acid--dna (338) 338
dna-binding proteins - metabolism (335) 335
doxorubicin - pharmacology (335) 335
models, molecular (327) 327
cell cycle (326) 326
dna gyrase (324) 324
resistance (321) 321
binding (319) 319
escherichia-coli (312) 312
topoisomerase (310) 310
article (302) 302
phosphorylation (298) 298
topoisomerase ii inhibitors - chemistry (293) 293
agents (286) 286
drug resistance, neoplasm (285) 285
antineoplastic agents - therapeutic use (282) 282
drug design (281) 281
cell division - drug effects (268) 268
doxorubicin (268) 268
multidisciplinary sciences (268) 268
dna repair (267) 267
enzyme inhibitors - chemistry (264) 264
molecular sequence data (262) 262
kinetics (261) 261
hela cells (260) 260
rats (259) 259
dna topoisomerases (258) 258
toxicology (257) 257
anti-infective agents - pharmacology (254) 254
gene expression (251) 251
novobiocin - pharmacology (246) 246
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6413) 6413
Japanese (34) 34
German (25) 25
Russian (23) 23
French (15) 15
Chinese (7) 7
Spanish (7) 7
Portuguese (4) 4
Italian (2) 2
Czech (1) 1
Finnish (1) 1
Korean (1) 1
Polish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Medicinal Chemistry, ISSN 0022-2623, 07/2011, Volume 54, Issue 14, pp. 5013 - 5030
On the basis of structures of known topoisomerase H catalytic inhibitors and initial molecular docking studies, bicyclic N-fused aminoimidazoles were predicted... 
DNA TOPOISOMERASE | CELLS | MOLECULAR-DYNAMICS | ETOPOSIDE | DOMAIN | CHEMISTRY, MEDICINAL | MECHANISM | ICRF-187 | ATP-BINDING-SITE | CANCER | FLEXIBLE DOCKING | Apoptosis - drug effects | Antineoplastic Agents - chemical synthesis | Humans | Imidazoles - chemistry | Cercopithecus aethiops | Structure-Activity Relationship | Topoisomerase II Inhibitors - chemistry | S Phase | HEK293 Cells | Antineoplastic Agents - pharmacology | Topoisomerase II Inhibitors - chemical synthesis | Imidazoles - chemical synthesis | Intercalating Agents - chemical synthesis | Binding Sites | Vero Cells | Cell Survival - drug effects | Antigens, Neoplasm | DNA-Binding Proteins - antagonists & inhibitors | Heterocyclic Compounds, 2-Ring - chemistry | Etoposide - pharmacology | Models, Molecular | Imidazoles - pharmacology | Intercalating Agents - pharmacology | Topoisomerase II Inhibitors - pharmacology | Antineoplastic Agents - chemistry | Intercalating Agents - chemistry | Molecular Dynamics Simulation | Heterocyclic Compounds, 2-Ring - pharmacology | Cell Movement - drug effects | G1 Phase | Animals | Cell Line, Tumor | Adenosine Triphosphatases - chemistry | DNA Topoisomerases, Type II | Fluorouracil - pharmacology | Adenosine Triphosphate - chemistry | Heterocyclic Compounds, 2-Ring - chemical synthesis | Drug Screening Assays, Antitumor | Index Medicus
Journal Article
Nature, ISSN 0028-0836, 04/2015, Volume 520, Issue 7546, pp. 239 - 242
Non-small-cell lung cancer is the leading cause of cancer-related death worldwide(1). Chemotherapies such as the topoisomerase II (TopoII) inhibitor etoposide... 
ADENOCARCINOMA | MULTIDISCIPLINARY SCIENCES | COMPLEXES | SWI/SNF | GROWTH | GENE-EXPRESSION | ANTAGONISM | MUTATIONS | CANCER | POLYCOMB | MICROARRAY DATA | Polycomb Repressive Complex 2 - antagonists & inhibitors | Lung Neoplasms - drug therapy | Apoptosis - drug effects | Humans | Lung Neoplasms - pathology | Molecular Targeted Therapy | Antineoplastic Agents, Phytogenic - therapeutic use | Nuclear Proteins - genetics | DNA Helicases - genetics | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Lung Neoplasms - enzymology | Carcinoma, Non-Small-Cell Lung - genetics | Genes, erbB-1 - genetics | Etoposide - pharmacology | Etoposide - therapeutic use | Topoisomerase II Inhibitors - pharmacology | Transcription Factors - genetics | Anaphase - drug effects | Enhancer of Zeste Homolog 2 Protein | Topoisomerase II Inhibitors - therapeutic use | Xenograft Model Antitumor Assays | Animals | Cell Line, Tumor | Mice | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Antineoplastic Agents, Phytogenic - pharmacology | Cell Cycle - drug effects | Protein research | Care and treatment | Oncology, Experimental | Genetic aspects | Research | Lung cancer, Non-small cell | Drug therapy | Gene expression | Cancer | Proteins | Genes | Lung cancer | Genetic engineering | Mutation | Kinases | Cancer therapies | Deoxyribonucleic acid--DNA | Tumors | Apoptosis | Etoposide | Chemotherapy | EZH2 inhibition | BRG1 | EGFR
Journal Article
Journal Article
Inorganic Chemistry, ISSN 0020-1669, 08/2013, Volume 52, Issue 15, pp. 8895 - 8908
Journal Article
Journal Article
Science, ISSN 0036-8075, 7/2011, Volume 333, Issue 6041, pp. 459 - 462
Journal Article
JBIC Journal of Biological Inorganic Chemistry, ISSN 0949-8257, 1/2012, Volume 17, Issue 1, pp. 81 - 96
DNA topoisomerases (I and II) have been one of the excellent targets in anticancer drug development. Here two chiral ruthenium(II) anthraquinone complexes, Δ-... 
Life Sciences | Biochemistry, general | Microbiology | Ruthenium(II) complexes | Topoisomerase inhibition | Cytotoxicity | DNA binding | Apoptosis | Cytotoxicity Apoptosis | DEOXYRIBONUCLEIC-ACID | INDIVIDUAL CELLS | DNA-BINDING | BIOCHEMISTRY & MOLECULAR BIOLOGY | NUCLEIC ACIDS | CHEMISTRY, INORGANIC & NUCLEAR | PROGRAMMED CELL-DEATH | POLYPYRIDYL COMPLEXES | ANTICANCER DRUGS | ANTITUMOR PROSTAGLANDINS | ETHIDIUM BROMIDE | Antineoplastic Agents - chemical synthesis | Humans | Structure-Activity Relationship | Thymus Gland - enzymology | Ruthenium - chemistry | Topoisomerase I Inhibitors - pharmacology | Topoisomerase II Inhibitors - chemistry | Cattle | Antineoplastic Agents - pharmacology | Topoisomerase II Inhibitors - chemical synthesis | Cell Death - drug effects | Topoisomerase I Inhibitors - chemistry | DNA Topoisomerases, Type II - metabolism | Escherichia coli - enzymology | DNA Topoisomerases, Type I - metabolism | Topoisomerase II Inhibitors - pharmacology | Antineoplastic Agents - chemistry | Topoisomerase I Inhibitors - chemical synthesis | Animals | Organometallic Compounds - chemical synthesis | Cell Line, Tumor | Organometallic Compounds - chemistry | Cell Proliferation - drug effects | Anthraquinones - chemistry | Organometallic Compounds - pharmacology | Drug Screening Assays, Antitumor | Chromatin | Ruthenium | Cell death | Analysis | DNA | Tumors
Journal Article
Bioorganic & Medicinal Chemistry, ISSN 0968-0896, 01/2017, Volume 25, Issue 1, pp. 338 - 349
Journal Article
European Journal of Medicinal Chemistry, ISSN 0223-5234, 03/2015, Volume 92, pp. 540 - 553
Journal Article
Current Medicinal Chemistry, ISSN 0929-8673, 12/2010, Volume 17, Issue 35, pp. 4270 - 4290
Journal Article
International Journal of Cancer, ISSN 0020-7136, 05/2013, Volume 132, Issue 10, pp. 2248 - 2257
Journal Article